#ESMO21 is looming, and we have a great group of experts lined up to help make sense of the news
The one international science conference I always enjoyed attending most has been ESMO. You mix some high-octane cancer R&D news with one of the best collection of global experts in the field. It was education, breaking news and a great European location all built into one packed weekend.
ASCO is great — but the ESMO package has been phenomenal.
We’ve lost the location, for now, but everything else is still in place for a big weekend. Managing editor Kyle Blankenship is leading the coverage on the news front, with the rest of the team pitching in to help. And we’ll have the full lineup of stories from the conference in a special report on Monday, Sept. 20. Be sure to check it out. And follow us on Twitter through the weekend for breaking news.
After that, Kyle and I will be doing back-to-back events. Kyle has a great panel lined up to discuss the weekend news and trends that should not be missed: Harvard’s Cigall Kadoch, Susan Galbraith, the new head of cancer R&D at AstraZeneca, Roy Baynes at Merck, and James Christensen at Mirati.
Just before that panel, I’ll be spending 30 minutes with Jake Van Naarden, the CEO of Lilly Oncology, covering his experience growing the oncology pipeline at Eli Lilly after making the leap from Loxo. Jake has a rep for straight talk that I enjoy, and I’m sure he has plenty of interesting insights on their development and BD strategy. Looking forward to that.
You can sign up for the event, which runs from noon ET to 1:30 pm ET, by following this link.
And don’t forget, in the middle of next week I’ll be hosting a special online presentation of this year’s Endpoints 11, featuring our latest class of up-and-coming private biotechs that bear close watching. Writing the Endpoints 11 is always the most fun I have all year. And this year’s group of CEOs have some things to say that should not be missed.
I hope you’ll join us. Here’s the link for the Endpoints 11.